EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK

Rui Cai, Alan A Martin iD, Yuchen Ge iD, Nancy A Risebrough iD, Katrin Haeussler iD, Christopher Compton iD, David M G Halpin iD, Afisi S Ismaila iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s475748 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Rui Cai und 7 weiteren Autor:innen. Beteiligte Einrichtung: ICON Health Economics, ICON plc, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Drug Costs, Benzyl Alcohols, Bronchodilator Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveDrug CostsBenzyl AlcoholsBronchodilator AgentsChlorobenzenesNebulizers and VaporizersQuinuclidinesAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsLungGlucocorticoidsHumansCost-Benefit AnalysisUnited KingdomTreatment OutcomeModels, EconomicAdministration, InhalationQuality-Adjusted Life YearsAgedMaleFemaleDrug CombinationsMiddle AgedTime FactorsState MedicineCost SavingsGlycopyrrolateAndrostadienes

Stichwörter der Autor:innen

GALAXY modelchronic obstructive pulmonary diseasecost-effectivenessfluticasone furoate/umeclidinium/vilanterolprobabilistic

Substanzen

Benzyl AlcoholsBronchodilator AgentsChlorobenzenesvilanterolQuinuclidinesGSK573719Adrenergic beta-2 Receptor AgonistsMuscarinic Antagonistsfluticasone furoateDrug Combinations

Autor:innen und Institutionen

  • ICON Health Economics, ICON plc, Amsterdam, the Netherlands.
  • Value Evidence and Outcomes, GSK, London, UK.
  • ICON Health Economics, ICON plc, Toronto, ON, Canada.
  • ICON Health Economics, ICON plc, Munich, Germany.
  • Global Medical, GSK, London, UK.
  • University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.

ORCID-Profile: Alan A Martin, Yuchen Ge, Nancy A Risebrough, Katrin Haeussler, Christopher Compton, David M G Halpin, Afisi S Ismaila

Zitieren

APA

Cai, R., Martin, A. A., Ge, Y., Risebrough, N. A., Haeussler, K., Compton, C., Halpin, D. M. G., & Ismaila, A. S. (2025). Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s475748

Vancouver

Cai R, Martin AA, Ge Y, Risebrough NA, Haeussler K, Compton C, et al. Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s475748

BibTeX
@article{Cai2025,
  author = {Cai, Rui and Martin, Alan A and Ge, Yuchen and Risebrough, Nancy A and Haeussler, Katrin and Compton, Christopher and Halpin, David M G and Ismaila, Afisi S},
  title = {Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s475748}
}
Kostenlos starten →